Genetic Variation and Immune Regulation in Liver Cancer - Dr. Olusegun Onabajo
Infections and Immunoepidemiology Branch Special Seminar
March 1, 2021 | 12:00 PM – 1:00 PM
Online via Webex
Olusegun Onabajo, Ph.D.
Staff Scientist, Laboratory of Translational Genomics,
Division of Cancer Epidemiology and Genetics, NCI
Dr. Onabajo is a staff scientist in the Laboratory of Translational Genomics, working with Ludmila Prokunina-Olsson, Ph.D. His research includes functional studies to examine the role of interferon lambda 4 (IFNL4) in the pathogenesis of HCV infection and development of liver cancer. He received his Ph.D. at the University of Maryland, College Park. There, he identified actin binding protein 1 (Abp1) as a link between B cell signaling and clathrin mediated endocytosis of cognate antigens. As a postdoctoral scientist at the Uniformed Services University for the Health Sciences, he studied mechanisms of B cell dysfunction during HIV. Most recently, his research described a novel isoform of ACE2, the SARS-CoV-2 receptor, that is induced by viral infections and interferons. Dr. Onabajo is interested in studying genetic and environmental risk factors for liver cancer with a focus on underrepresented minorities.